Adverse drug reactions: Part i

Southern Medical Journal

Volumn 103, Issue 10, 2010, Pages 1025-1030

  Wooten, James M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aadverse reactions; Adverse drug reactions; Drugs; Pharmacology

Indexed keywords

BETA LACTAM ANTIBIOTIC; HEPARIN; HYDRALAZINE; INSULIN; PENICILLIN G; PLACEBO; ROFECOXIB; TERFENADINE; DRUG;

ADENOMATOUS POLYP; ADVERSE DRUG REACTION; ANAPHYLAXIS; ARTHRITIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTACT DERMATITIS; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG OVERDOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HUMAN; HYPOGLYCEMIA; IATROGENIC DISEASE; IDIOSYNCRATIC DRUG REACTION; IMMUNE COMPLEX DISEASE; MEDICATION ERROR; PATIENT MONITORING; PENICILLIN ALLERGY; PREGNANT WOMAN; PRESCRIPTION; PROSPECTIVE STUDY; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADULT; AGE; AGED; CHILD; CLASSIFICATION; DRUG TOXICITY; FEMALE; PREGNANCY; RISK FACTOR;

ADULT; AGE FACTORS; AGED; CHILD; DRUG HYPERSENSITIVITY; DRUG TOXICITY; FEMALE; HUMANS; PHARMACEUTICAL PREPARATIONS; PREGNANCY; RISK FACTORS;

EID: 77958121509     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181f0c866     Document Type: Review

References (22)

1. Oyez Project, U.S. Supreme Court Media on Potter Stewart. Available at: http://www.oyez.org/justices/potter-stewart/. Accessed February 1, 2010.
2. Hohl CM, Robitaille C, Lord V, et al. Emergency physician recognition of adverse drug-related events in elder patients presenting to an emergency department. Acad Emerg Med 2005;12:197-205.
3. Farcas A, Bojita M. Adverse drug reactions in clinical practice: a causality assessment of a case of drug-induced pancreatitis. J Gastrointestin Liver Dis 2009;18:353-358.
4. Safety of Medicines: A Guide to Detecting and Reporting Adverse Drug Reactions. Geneva, Switzerland, World Health Organization, 2002. Available at: http://whqlibdoc.who.int/hq/2002/WHO-EDM-QSM-2002.2.pdf. Accessed January 26, 2010.
5. Kavitha D. Adverse drug reaction (ADR) monitoring and pharmacovigilance. J Pharm Res Health Care 2010;2:127-134.
6. Pharmacovigilance: ensuring the safe use of medicines. WHO Policy Perspectives on Medicines. World health Organization 2004. pg 1-5. Available at: http://whqlibdoc.who.int/hq/2004/WHO-EDM-2004.8.pdf. Accessed January 26, 2010.
7. Ann. Guidance for Industry - Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. 2005. US Food and Drug Administration. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ UCM126834.pdf. Accessed March 1, 2010.
8. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options [Review]. Am Fam Physician 2003;68:1781-1790.
9. Oberg KC. Adverse drug reactions. Am J Pharm Educ. 1999;63:199-204.
10. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205.
11. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006;26:601-608.
12. Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009;4:e4439.
13. Wooten J. Reporting adverse drug reactions. South Med J 2009;102: 345-346.
14. Wooten J. Adverse drug reactions. South Med J 2006;99:915.
15. Kelly WN. How can I recognize an adverse drug event? Medscape CME Pharmacists 2008. Available at: http://cme.medscape.com/viewarticle/569794?src= mp. Accessed March 2, 2010.
16. Pillans PI. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharm 2008;1:695-705.
17. Corrigan OP. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. Soc Sci Med 2002;55: 497-507.
18. Woloshin S, Schwartz LM. Bringing the FDA's information to market. Arch Intern Med 2009;169:1985-1987.
19. Meadows M. Why drugs get pulled from the market. FDA Consumer Magazine 2002. Available at: http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/ features/2002/102-drug.html. Accessed March 2, 2010.
20. Greenberger PA. 8. Drug allergy. J Allergy Clin Immunol 2006;117: S464-S470.
21. Ann. Guidance for industry: questions and answers regarding adverse event reporting and recordkeeping for dietary supplements as required by the dietary supplement and nonprescription drug consumer protection act. United States Food and Drug Administration 2007. Available at: http://www.fda.gov/Food/ GuidanceComplianceRegulatoryInformation/GuidanceDocuments/DietarySupplements/ ucm171383.htm. Accessed March 2, 2010.
22. Tseng DS, Kwong J, Rezvani F, et al. Angiotensin-converting enzymerelated cough among Chinese-Americans. Am J Med 2010;123:183.e11-183.e15.